Open main menu

CTI and Regenemm Healthcare

Regenemm Healthcare is the clinical product company that grew out of Creative Thinking Institute's research and development program.

CTI began with human performance, stress, adaptability, body movement, biosensors, sleep, circadian health, medical IoT and machine learning. Regenemm extends that lineage into clinician-led AI healthcare infrastructure: consultation capture, structured clinical documentation, patient-facing communication, consent-aware sharing, interoperability and audit-ready governance.

CTI's role is to keep the parent-company stance visible: AI should assist clinical work without hiding how outputs are produced, reviewed, shared or audited. Regenemm is the product surface where that stance becomes workflow, platform architecture and customer-facing trust evidence.

Relationship at a Glance

CTI

The parent company and research lineage. CTI holds the broader thinking across human performance, physiological data, healthcare AI governance and clinical workflow evolution.

Regenemm Healthcare

The product platform. Regenemm turns that research lineage into healthcare software for clinicians, patients, hospitals, referrers and care teams.

Shared governance

The operating model keeps clinician review, provenance, consent, audit, privacy, AI protection and responsible disclosure visible across public communication.

Why Regenemm Exists

Clinical conversations generate obligations. They need accurate records, readable patient summaries, clear referrer communication, safe follow-up actions and evidence of review.

Regenemm was created to address that workflow gap. It is not positioned as a generic chatbot or transcription-only tool. It is being built as clinical infrastructure where AI assists with drafting, organising and routing information while clinicians remain responsible for review and approval.

Product Surfaces

Regenemm Healthcare now describes a hub-and-spoke model:

  • Regenemm Voice for voice-to-record clinical documentation workflows.
  • Regenemm Link for patient-controlled sharing.
  • Regenemm Connect for governed interoperability pathways.
  • Regenemm Billing for claim-readiness and operational evidence.
  • Regenemm Triage for intake, priority signals and escalation preparation.
  • Regenemm Medico-legal for evidence packaging and disclosure-aware workflows.

The public product site maintains the current platform, security, clinical safety, API and trust documentation.

Cross-Site Trust Model

CTI and Regenemm should be read together:

  • CTI explains the research lineage, public governance stance, responsible AI philosophy and parent-company accountability.
  • Regenemm publishes the product, platform, trust center, security, clinical safety, API and customer review surfaces.
  • CTI does not duplicate detailed security evidence, infrastructure topology or customer-specific audit material. Those belong in controlled Regenemm trust and security workflows.
  • Both sites should consistently state that AI assists, clinicians decide, and patient-facing or externally shared clinical outputs require the right review, consent and release pathway.

How To Navigate